Medical notice: Educational content only. CanduCardio is intended for healthcare professionals and CanduTV for the general public. It does not replace clinical judgment or professional consultation.
Therapy group: SGLT2 inhibitors · Therapy: Canagliflozin vs placebo
Fully remote decentralized heart failure trial: canagliflozin improved KCCQ-measured symptoms at 12 weeks versus placebo, regardless of ejection fraction or diabetes status.
Published in Nat Med (2022)
Card generated automatically with AI from the abstract of the original publication and the trial registry; every figure was checked against those sources. It may contain errors: verify the data at the source before using it for clinical decisions.
Generated on October 14, 2026
Educational content only. CanduCardio is intended for healthcare professionals and CanduTV for the general public. It does not replace clinical judgment or professional consultation.